Dengue vaccine protective in human challenge study

In a paper published in Science Translational Medicine, researchers said dengue vaccine TV003 conferred complete protection in a Phase I challenge test. NIH developed the one-dose vaccine, which comprises four live attenuated recombinant dengue serotypes. The researchers were from The Johns Hopkins University, the University of Vermont and NIH's National Institutes of Allergy and Infectious Diseases (NIAID).

In the 41-subject study, all 21 people who received TV003 and were challenged six months later with an underattenuated form of dengue serotype 2 virus were protected completely from infection. All 20 who had received placebo and were challenged with the virus developed viremia, while 80% developed rash and 20% developed neutropenia. ...